Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Diagnostic & Testing Equipment
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MYGN
  • CUSIP: 62855J10
  • Web:
  • Market Cap: $1.61713 billion
  • Outstanding Shares: 68,118,000
Average Prices:
  • 50 Day Moving Avg: $24.67
  • 200 Day Moving Avg: $20.23
  • 52 Week Range: $15.15 - $32.54
  • Trailing P/E Ratio: 50.13
  • Foreward P/E Ratio: 21.93
  • P/E Growth: -3.04
Sales & Book Value:
  • Annual Revenue: $757.3 million
  • Price / Sales: 2.11
  • Book Value: $10.99 per share
  • Price / Book: 2.13
  • EBIDTA: $122.6 million
  • Net Margins: 4.26%
  • Return on Equity: 10.53%
  • Return on Assets: 6.64%
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 1.57%
  • Quick Ratio: 1.36%
  • Average Volume: 1.08 million shs.
  • Beta: 0.32
  • Short Ratio: 18.69
Frequently Asked Questions for Myriad Genetics (NASDAQ:MYGN)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its earnings results on Tuesday, May, 2nd. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.03. The firm earned $196.90 million during the quarter, compared to analysts' expectations of $188.89 million. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. View Myriad Genetics' Earnings History.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its fourth quarter earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $0.26-0.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $192-194 million, compared to the consensus revenue estimate of $188.50 million.

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2017?

13 equities research analysts have issued 1-year price targets for Myriad Genetics' shares. Their predictions range from $16.00 to $32.00. On average, they expect Myriad Genetics' stock price to reach $21.83 in the next year. View Analyst Ratings for Myriad Genetics.

What are analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Myriad Genetics has been trading above the broader Medical - Biomedical and Genetics industry. The company saw strong growth in EndoPredict test revenues and sequential growth in hereditary cancer volumes in the last reported quarter. Recently, Myriad’s companion diagnostic program received a major boost in a new cancer indication, in collaboration with AstraZeneca. We are also optimistic in regard to Myriad’s collaboration with BeiGene for development of companion diagnostics. On the flip side, gross margin scenario is disappointing. Also the company’s narrowing bottom line guidance for fiscal 2017 is discouraging, indicating a looming concern ahead. Currency fluctuations and stiff competition are other major headwinds for the company." (7/17/2017)
  • 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)
  • 3. UBS AG analysts commented, "MYGN reported FY4Q16 earnings on Tuesday. Reported sales of $187m were roughly in-line with our estimate of $187m and consensus estimates of $188m. Adjusted EPS of $0.36 was below both our estimate of $0.38 and consensus estimates of $0.37. Most importantly, for FY2017, management guided to sales of $740m – $760m and adj. EPS of $1.00 – $1.10 compared to consensus forecasts of $790m and $1.77. We have lowered our FY2017 EPS forecast by 43%." (8/10/2016)

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:

  • John T. Henderson M.D., Independent Chairman of the Board
  • Mark C. Capone, President, Chief Executive Officer, Director
  • Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
  • R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
  • Virginia C. Drosos, President of Assurex Health, Inc.
  • Alexander Ford, President of Myriad Genetic Laboratories, Inc.
  • Ralph L. McDade Ph.D., President of Myriad RBM, Inc
  • Bernard F. Tobin, President of Crescendo Bioscience, Inc
  • Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
  • Gary A. King, Executive Vice President - International Operations

Who owns Myriad Genetics stock?

Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (2.24%), Russell Investments Group Ltd. (1.58%), CWM LLC (0.79%), Spark Investment Management LLC (0.38%), Bank of Montreal Can (0.36%) and BB&T Corp (0.31%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Spark Investment Management LLC, Strs Ohio, Capstone Asset Management Co. and Creative Planning. View Insider Buying and Selling for Myriad Genetics.

Who bought Myriad Genetics stock? Who is buying Myriad Genetics stock?

Myriad Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Lebenthal Lisanti Capital Growth LLC, NGAM Advisors L.P., Hartford Investment Management Co., BB&T Corp, CIBC Asset Management Inc, State of Alaska Department of Revenue and Great West Life Assurance Co. Can. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of Myriad Genetics stock can currently be purchased for approximately $23.46.

MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
Community Ranking:  1.8 out of 5 ()
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  396 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 8 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 1.77)
Consensus Price Target: $21.83 (6.93% downside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00LowView Rating Details
7/14/2017Cowen and CompanyReiterated RatingHold$25.00LowView Rating Details
6/30/2017J P Morgan Chase & CoReiterated RatingUnderweight$16.00LowView Rating Details
5/8/2017Deutsche Bank AGBoost Price TargetSell$15.00 -> $20.00LowView Rating Details
5/3/2017Jefferies Group LLCReiterated RatingHold$18.00 -> $21.00MediumView Rating Details
3/13/2017StephensUpgradeEqual Weight -> Overweight$20.00MediumView Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralN/AView Rating Details
12/27/2016Barclays PLCReiterated RatingEqual Weight$22.00N/AView Rating Details
10/10/2016Bank of America CorporationReiterated RatingSellN/AView Rating Details
8/21/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 -> $21.00N/AView Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00N/AView Rating Details
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00N/AView Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00N/AView Rating Details
3/23/2016Goldman Sachs Group, Inc. (The)Boost Price Target$40.00N/AView Rating Details
9/20/2015William BlairReiterated RatingBuyN/AView Rating Details
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00N/AView Rating Details
(Data available from 7/28/2015 forward)


Earnings History for Myriad Genetics (NASDAQ:MYGN)
Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)
Earnings History by Quarter for Myriad Genetics (NASDAQ MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q3 2017$0.24$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
2017 EPS Consensus Estimate: $1.25
2018 EPS Consensus Estimate: $1.06
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.25$0.42$0.31
Q2 20173$0.23$0.46$0.33
Q3 20173$0.24$0.43$0.31
Q4 20173$0.26$0.38$0.30
Q1 20182$0.23$0.26$0.25
Q2 20182$0.26$0.27$0.27
Q3 20182$0.26$0.28$0.27
Q4 20182$0.27$0.29$0.28
(Data provided by Zacks Investment Research)


Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Myriad Genetics (NASDAQ:MYGN)
Insider Ownership Percentage: 6.20%
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.00View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Myriad Genetics (NASDAQ:MYGN)
Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline logoMyriad Genetics, Inc. (MYGN) Expected to Announce Quarterly Sales of $193.54 Million - July 26 at 10:36 AM logoMyriad Genetics, Inc. (NASDAQ:MYGN) Expected to Post Earnings of $0.26 Per Share - July 24 at 6:27 PM logoFinancial Analysis: Myriad Genetics (MYGN) vs. Alphatec Holdings (ATEC) - July 22 at 6:29 PM logoThe Best Stock in Utah: Myriad Genetics - July 22 at 6:45 AM logoMyriad Genetics, Inc. (MYGN) Given Average Rating of "Hold" by Brokerages - July 21 at 7:56 AM logoMyriad Genetics, Inc. (NASDAQ:MYGN) Upgraded at Zacks Investment Research - July 17 at 12:10 PM logoPiper Jaffray Companies Reaffirms Hold Rating for Myriad Genetics, Inc. (NASDAQ:MYGN) - July 15 at 10:16 AM logoCowen and Company Reaffirms "Hold" Rating for Myriad Genetics, Inc. (MYGN) - July 15 at 8:04 AM logoHTG Molecular Diagnostics (HTGM) vs. Myriad Genetics (NASDAQ:MYGN) Head to Head Analysis - July 14 at 9:54 AM logoMyriad Genetics (MYGN) versus Alphatec Holdings (ATEC) Head-To-Head Review - July 11 at 10:30 AM logoWhy Myriad Genetics Stock Rocketed 26.3% Higher in June - July 10 at 3:36 PM logoJPMorgan Checks In On Myriad Genetics Following 30% Rally - Benzinga - July 1 at 3:00 AM logoJ P Morgan Chase & Co Reiterates "Underweight" Rating for Myriad Genetics, Inc. (MYGN) - June 30 at 2:53 PM logo Brokerages Anticipate Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $193.54 Million - June 30 at 1:46 PM logoJPMorgan Checks In On Myriad Genetics Following 30% Rally - June 30 at 2:06 AM logoMyriad Genetics, Inc. (MYGN) Expected to Post Earnings of $0.26 Per Share - June 28 at 2:38 PM logoMyriad Genetics, Inc. (MYGN) Receives Average Recommendation of "Hold" from Brokerages - June 26 at 8:04 AM logoMyriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7% - Nasdaq - June 24 at 12:15 AM logoMyriad Genetics: Worth A Bet On Diagnostics Kit Pricing Expansion? - Seeking Alpha - June 22 at 8:22 AM logoVirginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region - June 19 at 5:47 PM logoVirginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region - June 19 at 11:19 AM logoMyriad Genetics, Inc. (MYGN) Upgraded at BidaskClub - June 17 at 4:48 PM logoINC Research Holdings (INCR) & Myriad Genetics (MYGN) Financial Comparison - June 16 at 8:48 AM logoCrescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress of Rheumatology - June 16 at 7:58 AM logoMyriad Genetics, Inc. (MYGN) Raised to "Hold" at BidAskClub - June 10 at 8:06 AM logoMyriad Genetics BRACAnalysis CDx in OlympiAD Results Positive - Nasdaq - June 6 at 9:07 AM logoMyriad Genetics (MYGN) Confirms BRACAnalysis CDx Test Identified Patients with ... - June 5 at 7:23 PM logoMyriad Genetics (MYGN) Confirms BRACAnalysis CDx Test Identified Patients with Metastatic Breast Cancer Who ... - - June 5 at 9:07 AM logoWhy Is Myriad Genetics (MYGN) Down 9.6% Since the Last Earnings Report? - Nasdaq - June 5 at 9:07 AM logoWhy Is Myriad Genetics (MYGN) Down 9.6% Since the Last Earnings Report? - June 5 at 9:07 AM logoMyriad Genetics (MYGN) Announces Results from 2000 Patient Study of myRisk Hereditary Cancer Test at ASCO - - June 4 at 11:52 PM logoMyriad Genetics Announces Results from a Large 2,000 Patient Clinical Utility Study of Its myRisk® Hereditary Cancer Test at the 53rd Annual Meeting of ASCO - June 4 at 9:57 AM logoETFs with exposure to Myriad Genetics, Inc. : June 2, 2017 - June 4 at 9:57 AM logoMyriad’s BRACAnalysis CDx® Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study - June 4 at 9:57 AM logo$193.54 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This Quarter - June 4 at 8:50 AM logoAnalyzing Myriad Genetics (MYGN) & Qiagen NV (QGEN) - June 3 at 10:38 PM logoMyriad Genetics (MYGN) Says 17 Additional Health Insurance Plans Cover EndoPredict - - June 2 at 8:07 PM logoMyriad Genetics, Inc. (MYGN) Expected to Announce Earnings of $0.26 Per Share - June 2 at 12:30 PM logoStock Traders Purchase High Volume of Myriad Genetics Call Options (MYGN) - June 2 at 7:04 AM logoMYGN Crosses Above Average Analyst Target - Nasdaq - June 1 at 7:33 PM logoMyriad Genetics to Present at the 2017 Goldman Sachs Global Healthcare Conference - GlobeNewswire (press release) - June 1 at 7:33 PM logoMyriad Genetics to Present at the 2017 William Blair Growth Stock Conference - GlobeNewswire (press release) - May 31 at 7:05 PM logoMyriad Genetics to Present at the 2017 William Blair Growth Stock Conference - May 31 at 4:34 PM logoMyriad Genetics to Present at the 2017 Goldman Sachs Global Healthcare Conference - May 30 at 6:26 PM logoMyriad Genetics Gets Extended Coverage for Prolaris Test - Nasdaq ... - Nasdaq - May 29 at 3:19 PM logoMyriad Genetics, Inc. (MYGN) Sees Significant Decrease in Short Interest - May 28 at 7:16 AM logoMyriad Genetics (MYGN) Announces Expanded Medicare Coverage ... - - May 26 at 7:37 PM logoMyriad Genetics (MYGN) Announces Expanded Medicare Coverage of Prolaris Test - May 26 at 4:33 AM logoMedicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer - May 26 at 4:33 AM logoETFs with exposure to Myriad Genetics, Inc. : May 22, 2017 - May 22 at 6:00 PM



Myriad Genetics (MYGN) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by Staff